Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Turner

Showing results (121-130 of 138) with videos related to

Pageof 14
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2025
Camizestrant in combination with three globally approved CDK4/6 inhibitors in women with ER+, HER2- advanced breast cancer: Results from SERENA-1Richard D Baird, Begoña Bermejo de Las Heras, Manuel Ruiz-Borrego, et al.
European Journal of Cancer (Oxford, England : 1990)|April 16, 2022
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL studyMiguel Martín, Christoph Zielinski, Manuel Ruiz-Borrego, et al.
Nature Communications|December 2, 2017
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistanceLesley-Ann Martin, Ricardo Ribas, Nikiana Simigdala, et al.
European Journal of Cancer (Oxford, England : 1990)|April 9, 2025
Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b studyPhilippe L Bedard, Komal L Jhaveri, Melissa K Accordino, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 22, 2020
Variability in the Management of Adults With Pulmonary Nontuberculous Mycobacterial DiseaseGetahun Abate, Jack T Stapleton, Nadine Rouphael, et al.
Trials|January 11, 2024
Sertraline for anxiety in adults with a diagnosis of autism (STRATA): study protocol for a pragmatic, multicentre, double-blind, placebo-controlled randomised controlled trialDheeraj Rai, Doug Webb, Amanda Lewis, et al.
The Lancet. Oncology|October 10, 2025
Clinical potential of whole-genome data linked to mortality statistics in patients with breast cancer in the UK: a retrospective analysisDaniella Black, Helen Ruth Davies, Gene Ching Chiek Koh, et al.
Faraday Discussions|August 23, 2024
Enzyme evolution, engineering and design: mechanism and dynamics: general discussionCarlos Acevedo-Rocha, Lukasz Berlicki, Uwe T Bornscheuer, et al.
Faraday Discussions|August 27, 2024
Biocatalysis for industry, medicine and the circular economy: general discussionAbdulrahman Alogaidi, Fraser Armstrong, Amulyasai Bakshi, et al.
JCO Precision Oncology|September 2, 2025
Reply to: Germline and Somatic <i>BRCA1/2</i> Mutations in Breast Cancer Treatment StrategiesEric Hahnen, Jan Hauke, Karen Gelmon, et al.
Pageof 14

Showing results (121-130 of 138) with videos related to

Sort By:
Pageof 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2025
Camizestrant in combination with three globally approved CDK4/6 inhibitors in women with ER+, HER2- advanced breast cancer: Results from SERENA-1Richard D Baird, Begoña Bermejo de Las Heras, Manuel Ruiz-Borrego, et al.
European Journal of Cancer (Oxford, England : 1990)|April 16, 2022
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL studyMiguel Martín, Christoph Zielinski, Manuel Ruiz-Borrego, et al.
Nature Communications|December 2, 2017
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistanceLesley-Ann Martin, Ricardo Ribas, Nikiana Simigdala, et al.
European Journal of Cancer (Oxford, England : 1990)|April 9, 2025
Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b studyPhilippe L Bedard, Komal L Jhaveri, Melissa K Accordino, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 22, 2020
Variability in the Management of Adults With Pulmonary Nontuberculous Mycobacterial DiseaseGetahun Abate, Jack T Stapleton, Nadine Rouphael, et al.
Trials|January 11, 2024
Sertraline for anxiety in adults with a diagnosis of autism (STRATA): study protocol for a pragmatic, multicentre, double-blind, placebo-controlled randomised controlled trialDheeraj Rai, Doug Webb, Amanda Lewis, et al.
The Lancet. Oncology|October 10, 2025
Clinical potential of whole-genome data linked to mortality statistics in patients with breast cancer in the UK: a retrospective analysisDaniella Black, Helen Ruth Davies, Gene Ching Chiek Koh, et al.
Faraday Discussions|August 23, 2024
Enzyme evolution, engineering and design: mechanism and dynamics: general discussionCarlos Acevedo-Rocha, Lukasz Berlicki, Uwe T Bornscheuer, et al.
Faraday Discussions|August 27, 2024
Biocatalysis for industry, medicine and the circular economy: general discussionAbdulrahman Alogaidi, Fraser Armstrong, Amulyasai Bakshi, et al.
JCO Precision Oncology|September 2, 2025
Reply to: Germline and Somatic <i>BRCA1/2</i> Mutations in Breast Cancer Treatment StrategiesEric Hahnen, Jan Hauke, Karen Gelmon, et al.
Pageof 14